Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO

Follow-Up May Explain Lower Cytopenias, KOL Says

 
• By Alaric DeArment
Regeneron
• Source: Shutterstock: lev radin

More from ASCO

More from Conferences